Skip to content

Safety & efficacy of the sheets-type ELF-ELME therapy for depression

Safety and efficacy of the sheets-type ELF-ELME (extremely low frequency, extremely low magnetic environment) device in the treatment of depressive disorders: a preliminary exploratory open-label trial - Safety & efficacy of the sheets-type ELF-ELME therapy for depression

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs042240061
Enrollment
4
Registered
2024-07-25
Start date
2024-09-18
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depressive episode (DSM-5) depression

Interventions

A sheets-type magnetic field stimulator incorporating a device that generates an extremely low frequency-weak magnetic fields is worn for two hours a day.

Sponsors

Tachibana Masako
Lead Sponsor
Ono Kinji
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. 18 to 75 years old, male and female 2. Patients who met the diagnostic criteria for a depressive episode according to DSM-5 3. Patients with a total MADRAS score of 22 or higher at baseline. 4. Patients whose written consent to participate in this study has been obtained from them.

Exclusion criteria

Exclusion criteria: 1.Patients who met the following disorders according to the DSM-5 (delirium, dementia,amnesia and other cognitive disorders; schizophrenia and other psychotic disorders; mental retardation, etc.) 2.Patients who met the diagnostic criteria for substance abuse and substance dependence according to the DSM-5 within 24 weeks (excluding nicotine-related or caffeine-related disorders) 3.Patients with intracranial lesions with a history of or at risk for epilepsy/convulsive seizures. Patients who take drugs that risk lowering the convulsive threshold; tricyclic antidepressants, maprotiline, theophylline, methylphenidate, ketamine, etc. 4.Patients with a score of 4 or higher on item 10 (suicidal thoughts) of the MADRAS who are at high risk of suicide, or patients who are judged by the principal investigator to be at high risk of suicide. 5.Patients who have had a change in pharmacotherapy within 4 weeks 6.Patients who received other investigational drugs or standard psychotherapy such as cognitive behavioral therapy, interpersonal therapy, or psychoanalytic therapy within 16 weeks 7.Patients who received electroconvulsive therapy or high intensity light therapy within 16 weeks 8.Patients with serious complications such as diseases of the liver, kidney, blood, respiratory organs, digestive organs, cardiovascular system, metabolic and electrolyte abnormalities, or hypersensitivity 9.Patients with metals in close proximity to the stimulation site (cochlear implants, magnetic clips, stimulators such as deep brain stimulation or vagus nerve stimulation, intracranial titanium products, magnetized dentures or implants), cardiac pacemakers 10.pregnant patients 11.Patients who, for any other reason, are judged by the investigator to be inappropriate for participation in the study.

Design outcomes

Primary

MeasureTime frame
Presence of adverse events

Secondary

MeasureTime frame
Change in MADRS Scores Change in Clinical Global Impression - Improvement (CGI-I) Change in Clinical Global Impression - Severity (CGI-S) Change in AI-MADRS Wearing compliance rate Comparison of efficacy and safety between head-worn and bedding-type devices using the dataset from a previous study (head-worn ELF-ELME generator, Asian J Psychiatr 96:104036, 2024) and the dataset from this study

Contacts

Public ContactMasako Tachibana

Nagoya University Hospital

tachibana.masako.i4@f.mail.nagoya-u.ac.jp+81-52-744-2282

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026